Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial

Jun Tian(Harvard University), Ryan B. Corcoran(Massachusetts General Hospital), Matthew B. Yurgelun(Dana-Farber Cancer Institute), William B. Bradford(Harvard University), Jonathan Braverman(Innovative Genomics Institute), Rebecca Leary(Howard Hughes Medical Institute), Joy X. Jarnagin(Massachusetts General Hospital), Jeffrey A. Meyerhardt(CancerCare), Shadmehr Demehri(Massachusetts General Hospital), Giulia Siravegna(University of Turin), Aparna R. Parikh(Massachusetts General Hospital), Vjola Jorgji(Harvard University), Sherry Chao(Broad Institute), A. Gemma(Harvard University), Arlene H. Sharpe(Brigham and Women's Hospital), Islam Baiev(Massachusetts General Hospital), Thomas A. Abrams(Dana-Farber Cancer Institute), Katie Kanter(Massachusetts General Hospital), Marios Giannakis(Broad Institute), Karin Pelka(Broad Institute), Nir Hacohen(Cambridge Hospital), Gary Chi(Harvard University), Edmond Wong(Harvard University), Nadine J. McCleary(Harvard University), Kelly P. Burke(Harvard University), Maxwell Spurrell(Harvard University), Andrea C. Enzinger(Harvard University), David Lieb(Broad Institute), Julian M. Hess(Broad Institute), Emily E. Van Seventer(Massachusetts General Hospital), David P. Ryan(East Carolina University), Samuel J. Klempner(Broad Institute), Princy Sindurakar(Harvard University), Alexa Michel(Harvard University), Catarina D. Campbell(Broad Institute), Isobel J. Fetter(Harvard University), Jeffrey W. Clark(Massachusetts General Hospital), Peter C. Enzinger(Dana-Farber Cancer Institute), Ömer Yılmaz(Ondokuz Mayıs University), Jonathan Chen(Broad Institute), Mei Huang(First Affiliated Hospital of Guangzhou Medical University), Tomonori Oka(Massachusetts General Hospital), Arnav Mehta(California Institute of Technology), Jill N. Allen(Harvard University), Gad Getz(Broad Institute)
Nature Medicine
January 26, 2023
Cited by 197


Related Papers